Yttrium (90Y) clivatuzumab tetraxetan

Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer.[1] The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

Yttrium (90Y) clivatuzumab tetraxetan
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetMUC1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6496H9952N1716O2014S44
Molar mass145723.71 g·mol−1
 NY (what is this?)  (verify)

The drug was developed by Immunomedics, Inc.

In March 2016 the phase III PANCRIT-1 trial in metastatic pancreatic cancer was terminated early due to lack of improvement of overall survival.[3]

References
  1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan" (PDF). American Medical Association.
  2. WHO Drug Information
  3. Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic Cancer. March 2016


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.